Abstract
The 5T33 multiple myeloma is one of a series of transplantable murine myelomas arising spontaneously in C57BL/KaLwRij mice. This study describes the establishment and characterisation of the 5T33 murine myeloma in vitro as a cultured cell line in terms of its morphology, growth rate, expression of paraprotein (IgG2b) and tumorigenicity in syngeneic animals. The 5T33 cell line has been in continuous culture for over 10 months and has achieved more than passage 34. In culture, 5T33 myeloma grows as single cells or in small clusters of loosely adherent cells on an adherent stromal cell layer. Maximum doubling time is approximately 25 h, and over 90% of the cells express cytoplasmic IgG2b paraprotein. The cultured 5T33 myeloma cells are highly tumorigenic in C57BL/KaLwRij mice with as few as 500 cells inducing paralysis and death as early as day 36 post-tumour inoculation. Kinetics of tumour development and detection of IgG2b paraprotein are dose dependent. Two weeks following intravenous inoculation of 5 x 10(5) cultured 5T33 myeloma cells, tumour cells were readily identified in the bone marrow. By 3 weeks post-tumour inoculation, 5T33 myeloma cells were found in various tissues throughout the animal. Studies are now underway to determine the sensitivity of this cell line to various therapeutic modalities.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Manning, L., Berger, J., O'Donoghue, H. et al. A model of multiple myeloma: culture of 5T33 murine myeloma cells and evaluation of tumorigenicity in the C57BL/KaLwRij mouse. Br J Cancer 66, 1088–1093 (1992). https://doi.org/10.1038/bjc.1992.415
Issue Date:
DOI: https://doi.org/10.1038/bjc.1992.415
This article is cited by
-
Preclinical animal models of multiple myeloma
BoneKEy Reports (2016)
-
Aloperine executes antitumor effects against multiple myeloma through dual apoptotic mechanisms
Journal of Hematology & Oncology (2015)
-
Age matters:  Young T lymphocytes offer better protection from myeloma proliferation
Immunity & Ageing (2013)
-
Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells
Gene Therapy (2011)
-
Antitumour and antiangiogenic effects of Aplidin® in the 5TMM syngeneic models of multiple myeloma
British Journal of Cancer (2008)